SCANDINAVIAN CHEMOTECH Aktie

 

Retransmission of the press release that was published, with the associated MAR label, on July 1st, 2025 at 16:45. Scandinavian ChemoTech AB's Animal Care division proudly announces record-breaking sales in the second quarter of 2025. With continued momentum from a strong start to the quarter, the team achieved sales totaling USD 390,000, representing nearly 60% of the total revenue generated during all of 2024 — in just one quarter. Including the first quarter, ChemoTech's Animal Care division has reached USD 630,000 in total sales during the first half of 2025. This is almost the same...

Scandinavian ChemoTech AB's Animal Care division proudly announces record-breaking sales in the second quarter of 2025. With continued momentum from a strong start to the quarter, the team achieved sales totaling USD 390,000, representing nearly 60% of the total revenue generated during all of 2024 — in just one quarter. Including the first quarter, ChemoTech's Animal Care division has reached USD 630,000 in total sales during the first half of 2025. This is almost the same as the total sales for all of 2024, showing strong demand and good results from the company's Key Account strategy....

Scandinavian Chemotech AB announces that the entire management team and board of directors have fully subscribed to the warrant programs approved by shareholders at the Annual General Meeting held on 13 May 2024. The warrant program includes 470,000 warrants allocated to management and 690,000 to the board of directors. Both programs have been fully subscribed, underscoring the strong alignment of interests between company leadership and shareholders. “This is a clear signal of commitment and confidence from both our board and management in the future of Scandinavian ChemoTech,” said...

Scandinavian ChemoTech AB (publ) hereby publishes the Interim Report for Q1 2025. First-quarter sales reached 2 472 KSEK, which is the best quarter so far. All sales originated from Animal Care. The report is attached to this press release and can also be downloaded from the company's website. First quarter 2025 · Net sales amounted to 2 472 KSEK (1 345) · Profit/loss after financial items amounted to -3 322 KSEK (-3 203) · Earnings per share amounted to -0,14 SEK (-0,18) · Cash flow from operating activities amounted to -1 239 KSEK (-4 853) · All orders were delivered...

Retransmission of the press release that was published, with the associated MAR label, on May 1st, 2025, at 06:15 CET. Scandinavian ChemoTech is proud to announce a record-breaking performance in April, with order intake near the total for the entire first quarter of the year. This achievement marks a significant milestone and sets a strong tone for the beginning of Q2. “We are thrilled with the momentum we have seen as we move into the second quarter," said Mohan Frick, CEO. "Nearing our Q1 order volume in just one month is a testament to the hard work of our team and the trust our...

Scandinavian ChemoTech is proud to announce a record-breaking performance in April, with order intake near the total for the entire first quarter of the year. This achievement marks a significant milestone and sets a strong tone for the beginning of Q2. “We are thrilled with the momentum we have seen as we move into the second quarter," said Mohan Frick, CEO. "Nearing our Q1 order volume in just one month is a testament to the hard work of our team and the trust our customers place in Tumor-Specific Electroporation (TSE)."   While the company is optimistic about the trajectory for Q2,...

Scandinavian ChemoTech's Animal Care is excited to announce a partnership with one of the largest veterinary groups in the U.S., marking a major step in expanding the footprint of vetIQure™. For the first time, multiple locations within a single group are simultaneously adopting our advanced TSE technology. This specialty and emergency clinic group, staffed by board-certified and residency-trained veterinarians, has integrated vetIQure™ TSE to enhance oncology treatments. The technology offers a safe, effective, and minimally invasive tumor care solution, preserving healthy tissue while...

Scandinavian ChemoTech's Animal Care continues its momentum, achieving an order intake exceeding USD 230,000 (2.3 MSEK) in Q1 2025 which makes it the best quarter so far in regards of sales. This reinforces the steady growth in revenue observed in previous quarters, signaling a positive long-term trend toward profitability. A key factor behind this success is the increasing recognition of the clinical and financial benefits of TSE treatments. Customer satisfaction remains a cornerstone of our growth, with clients expressing appreciation for both the effectiveness of our technology and the...

Scandinavian ChemoTech continues to drive its Animal Care operations forward by securing yet another commercial collaboration with a global operator of equine hospitals, with an initial transaction valued at approximately EUR 45,000. This partnership strengthens the company's mission to revolutionize veterinary oncology with Tumor-Specific Electroporation (TSE). The group has grown to over 50 clinics across Europe and North America, employing 1,500+ professionals, with plans to gradually expand TSE to more locations. After a long evaluation period, which included approximately 20 treatments...

Scandinavian ChemoTech AB (publ) hereby publishes the Year-End Report for 2024. Fourth-quarter sales reached 2 041 KSEK, which is the best quarter in 2024. Total annual sales amounted to 6 566 KSEK—entirely from Animal Care. If reported separately, Animal Care would show a positive result in 2024. According to our calculations the operating profit would be approximately 475 KSEK.  The report is attached to this press release and can also be downloaded from the company's website. (https://chemotech.se/financial-reports/) Fourth quarter 2024...

Scandinavian ChemoTech AB (publ) hereby publishes the Year-End Report for 2024. Fourth-quarter sales reached 2 041 KSEK, which is the best quarter in 2024. Total annual sales amounted to 6 566 KSEK—entirely from Animal Care. If reported separately, Animal Care would show a positive result in 2024. According to our calculations the operating profit would be approximately 475 KSEK.  The report is attached to this press release and can also be downloaded from the company's website. (https://www.chemotech.se/investor-relations/financial-reports/) Fourth quarter 2024...

Scandinavian ChemoTech AB (publ) hereby publishes the Year-End Report for 2024. Fourth-quarter sales reached 2 041 KSEK, which is the best quarter in 2024. Total annual sales amounted to 6 566 KSEK—entirely from Animal Care. If reported separately, Animal Care would show a positive result in 2024. According to our calculations the operating profit would be approximately 475 KSEK.  The report is attached to this press release and can also be downloaded from the company's website. (https://www.chemotech.se/investor-relations/financial-reports/) Fourth quarter 2024...

ChemoTech is pleased to announce the signing of new restructured loan agreements to replace its previous short-term bridge financing. The new agreements include a 2.4 MSEK loan from two external investors and a 3.4 MSEK loan from a Board member and the CEO. All loans retain the same terms as previous agreements, except for an extended duration from six to twelve months, to 31 of January 2026. These measures are part of ChemoTech's ongoing efforts to strengthen and optimize its financial structure, reducing the need for share issues to repay matured loans and creating an opportunity to...

Scandinavian ChemoTech is pleased to announce that our Animal Care operations would already be showing a positive cash flow if we reported our business areas separately. This underscores the importance of the structural and strategic changes we are implementing in 2025. After thorough analysis and reallocating costs from Human to Animal Care, we learned that combining financial data from all areas has masked the strong performance of our animal care division. Simulated separate reporting shows that our animal care operations were not only sustainable but also profitable in 2024. Notably,...

Scandinavian ChemoTech AB, in line with the structural changes for the group published on December 30, 2024, has decided to implement measures aimed at achieving financial sustainability. As part of this strategy, the Company will conclude its collaboration with Medical Director Dr. Suhail Sayeed Mufti. This decision follows a thorough evaluation of the Company's priorities and resources, ensuring an optimized focus on revenue growth within the Animal Care business. By reallocating resources to areas with the highest potential for growth, Scandinavian ChemoTech aims to enhance its...

Scandinavian ChemoTech AB has decided to change language from Swedish to English for disclosure of information. The change will take place with immediate effect which means that the Company will only communicate financial reports and press releases in English from today, January 9, 2025. Certain information will still be published in Swedish due to current regulations.   The change of language to English is a consequence of the fact that the Company largely operates in markets outside of Sweden and is experiencing increased interest from international stakeholders such as customers...

Since 2021, Scandinavian ChemoTech has operated two distinct business units - Human Care and Animal Care. While Human Care was the group's initial focus, the Board of Directors has made key decisions to support the independence and growth of the two separate entities. By separating the successful cash generating Animal Care unit from the more complex processes of Human Care, where much of the company's burn rate is concentrated, resources can be reallocated to boost sales activities within Animal Care. With these changes the company anticipates annual savings of 2-3 MSEK, which can be...

Animal Care is on track to close 2024 on a high note, with sales in the fourth quarter already reaching approximately 1,500 KSEK and projected to surpass 6,000 KSEK for the full year. This highlights the increasing adoption and success of our vetIQure™ TSE system and treatment kits in the veterinary market.   A key driver of this growth is the rising number of repeat purchases from existing customers. This demonstrates not only the trust our customers place in the vetIQure™ TSE system but also its growing utilization in veterinary practices—an encouraging sign of its effectiveness and...

Animal Care is on track to close 2024 on a high note, with sales in the fourth quarter already reaching approximately 1,500 KSEK and projected to surpass 6,000 KSEK for the full year. This highlights the increasing adoption and success of our vetIQure™ TSE system and treatment kits in the veterinary market.   A key driver of this growth is the rising number of repeat purchases from existing customers. This demonstrates not only the trust our customers place in the vetIQure™ TSE system but also its growing utilization in veterinary practices—an encouraging sign of its effectiveness and...

Scandinavian ChemoTech AB's subsidiary dedicated to Animal Care has entered a clinical partnership with the Norwegian University of Life Sciences (NMBU) Hospital for Equine Medicine. Following an extensive evaluation period, NMBU's Equine team, led by Professor and DVM Cathrine Fjordbakk, has decided to integrate ChemoTech's Tumour-Specific Electroporation (TSE) therapy into their routine treatment offerings. This partnership aims to set new standards in veterinary oncology and reach new scientific milestones.   This collaboration and commercial agreement not only strengthen the...